• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Update: Annual Changes to the Nasdaq-100® Index

    12/12/23 6:00:00 PM ET
    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NDAQ alert in real time by email

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023.

    The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.

    Information

    For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/.

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Nasdaq Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Relations ContactsInvestor Relations Contact  
    Name: Camille StaffordName: Index Client Services  
    Email: [email protected]

    Email  [email protected]  
      
    Name: Jennifer Lawson 
    Email: [email protected] 
      


    Primary Logo

    Get the next $NDAQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDAQ
    $PFE
    $SGEN
    $TTWO

    CompanyDatePrice TargetRatingAnalyst
    Take-Two Interactive Software Inc.
    $TTWO
    10/9/2025$270.00 → $300.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    7/28/2025$265.00Overweight
    Wells Fargo
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    Take-Two Interactive Software Inc.
    $TTWO
    2/19/2025$250.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Buy → Neutral
    UBS
    More analyst ratings

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Declares Fourth-Quarter 2025 Dividend

    Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discov

    10/9/25 4:30:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date September 30, 2025

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of September 30, 2025, short interest in 3,366 Nasdaq Global MarketSM securities totaled 14,078,324,727 shares compared with 14,035,983,054 shares in 3,341 Global Market issues reported for the prior settlement date of September 15, 2025. The mid-September short interest represents 2.16 days compared with 2.49 days for the prior reporting period. Short interest in 1,675 securities on The Nasdaq Capital MarketSM totaled 3,220,349,947 shares at the end of the settlement date of September 30, 2025, compared with 3,110,176,592 shares in 1,673 securities for the previous reporting period. This represents a 1.00 day a

    10/9/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025

    Data from the CLARITY study will provide insights on acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections Four-year analysis from the OPERA cohort examines continued use of Vocabria + Rekambys and virologic outcomes across age groups 96-week virological efficacy data for Dovato vs Biktarvy will be presented from the PASO DOBLE head-to-head study Safety and tolerability results from the phase IIb EMBRACE study will be presented for VH109 (N6LS), an investigational broadly neutralising antibody administered every four months, in combination with cabotegravir long-acting for HIV treatment ViiV Healthcare, the global specialist HIV compa

    10/9/25 9:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson reiterated coverage on Take-Two with a new price target

    DA Davidson reiterated coverage of Take-Two with a rating of Buy and set a new price target of $300.00 from $270.00 previously

    10/9/25 11:01:25 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Wells Fargo initiated coverage on Take-Two with a new price target

    Wells Fargo initiated coverage of Take-Two with a rating of Overweight and set a new price target of $265.00

    7/28/25 9:00:36 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    NASDAQ upgraded by UBS with a new price target

    UBS upgraded NASDAQ from Neutral to Buy and set a new price target of $115.00

    7/25/25 8:52:40 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gordon William B was granted 1,033 shares, increasing direct ownership by 2% to 61,930 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    10/3/25 4:31:39 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Siminoff Ellen F was granted 1,064 shares, increasing direct ownership by 15% to 8,255 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    10/3/25 4:30:23 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Viera Paul E was granted 1,054 shares, increasing direct ownership by 7% to 16,991 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    10/3/25 4:29:00 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nasdaq Inc.

    SCHEDULE 13G/A - NASDAQ, INC. (0001120193) (Subject)

    10/6/25 5:18:36 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form S-8 filed by Take-Two Interactive Software Inc.

    S-8 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    9/26/25 4:29:41 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form S-8 filed by Take-Two Interactive Software Inc.

    S-8 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    9/26/25 4:25:41 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Leadership Updates

    Live Leadership Updates

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Mafia: The Old Country Now Available Worldwide

    Dive into the roots of organized crime in 1900s Sicily with a compelling new cast of characters today Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment in the acclaimed Mafia franchise, is now available worldwide for PlayStation®5 (PS5®), Xbox Series X|S, and PC via Steam. The story will take players back in time to 1900s Sicily, which has been painstakingly created with the utmost authenticity and detail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808972468/en/Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment i

    8/8/25 10:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Financials

    Live finance-specific insights

    View All

    Pfizer Declares Fourth-Quarter 2025 Dividend

    Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discov

    10/9/25 4:30:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Take-Two Interactive Software, Inc. to Report Second Quarter Fiscal Year 2026 Results on Thursday, November 6, 2025

    Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today announced that it plans to report financial results for its second quarter of Fiscal Year 2026, ended September 30, 2025, after the market close on Thursday, November 6, 2025. The Company plans to hold a conference call to discuss its results at 4:30 p.m. Eastern Time, which can be accessed by dialing (800) 715-9871 or (646) 307-1963 (conference ID: 9711440). A live, listen-only webcast and a replay of the call will be available at http://take2games.com/ir. About Take-Two Interactive Software Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher, and marketer of interactive entertainm

    10/9/25 8:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance